Myositis
Myositis
Comparative, Double-Blind, Investigational Study Evaluating the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)
- You Must:
- Be diagnosed of definite or probable IIM
- Demonstrate muscle weakness
- Have active disease despite adequate prior treatment experience with corticosteroids, immunosuppressants, or biologic medications
- You Must Not:
- Have Inclusion Body Myositis or myositis other than IIM
- Have been treated with rituximab in the past year or any other biologic treatment or IVIG in the past 6 months
- This is a 52 week long investigational study – Visits occur at Screening, Baseline, and about every 4 weeks afterwards
- For more information, please contact (610) 868-1336 ext. 112